Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy. PATIENTS AND METHODS: A total of 1239 patients from five randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was evaluated by the Kaplan-Meier method, log-rank tests and Cox models. RESULTS: In 664 tumors, no mutation was detected, 462 tumors were diagnosed with KRAS-, 39 patients with NRAS- and 74 patients with BRAF-mutation. Mutations in KRAS were associated with inferior progression-free survival (PFS) and overall survival (OS) [multivariate hazard ratio (HR) for PFS: 1.20 (1.02-1.42), P = 0.03; multivariate HR for OS: 1.41 (1.17-1.70), P < 0.001]. BRAF mutation was also associated with inferior PFS [multivariate HR: 2.19 (1.59-3.02), P < 0.001] and OS [multivariate HR: 2.99 (2.10-4.25), P < 0.001]. Among specific KRAS mutation variants, the KRAS G12C-variant (n = 28) correlated with inferior OS compared with unmutated tumors [multivariate HR 2.26 (1.25-4.1), P = 0.001]. A similar trend for OS was seen in the KRAS G13D-variant [n = 71, multivariate HR 1.46 (0.96-2.22), P = 0.10]. More frequent KRAS exon 2 variants like G12D [n = 152, multivariate HR 1.17 (0.86-1.6), P = 0.81] and G12V [n = 92, multivariate HR 1.27 (0.87-1.86), P = 0.57] did not have significant impact on OS. CONCLUSION: Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Approximately 45% of patients diagnosed with mCRC have KRAS mutations, and the presence of mutations is important both in terms of prognosis [9,10].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [9]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the KRAS p.G12C mutation is associated with poorer prognosis in terms of progression-free survival (PFS) and overall survival (OS) compared to other KRAS mutations as well as KRAS wild-type tumors.4-7”
From Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A pooled analysis by the Arbeitsgemeinschaft Internistische Onkologie [AIO] study group revealed that KRAS G12C mutation was significantly associated with lower OS compared with tumors with no KRAS mutations [16]”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with other KRASm, including KRAS G12A/D/S/V and KRAS G13D, had OS times ranging from 17.6 to 25.2 months.51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
In the citing paper
“A post hoc analysis of pooled clinical data from 1239 patients from 5 randomized trials, in which patients with mCRC were treated with chemotherapy with or without bevacizumab as first-line treatment (67%), reported that patients harboring KRAS G12C had the shortest median OS (16.8 [95% CI: 15.6, 18.0] months).51”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 3×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Despite the limitation of sample size in single trials, BRAF mutation represents a consistently poor prognostic marker in the context of mCRC treatment [1, 11, 12], associated with rapid clinical deterioration after progression to initial therapy [12].”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740 · cited 1×
“patients andmethods studies This analysis is based on individual patient data from five first-line trials in mCRC: FIRE-1 [14, 15], FIRE-3 (only bevacizumab-arm) [2, 16, 17], AIO KRK 0604 [18], AIO KRK 0207 [19] and RO91 [20].”
MethodSelf-citationCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 3×
“well with recent reports of first-line treatment in mCRC [5, 24].”
BackgroundResultVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Research works printed but not linked: 1
- 19. Stintzing S, Jung A, Rossius L, Modest DP et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3 A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. In ESMO/ECCO, 2013; Abstract E17-7073.
Cited by
Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx175 · Cited by 838
Self-citationTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01441-4 · Cited by 482
“Likewise, a pooled analysis including 1239 patients with metastatic CRC from five randomized trials indicated that patients who harbored the KRASG12C mutation were associated with worse OS than patients with nonmutated tumors [29].”
BackgroundSotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Self-citationColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320
Self-citationKRAS: From undruggable to a druggable Cancer Target
Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 242
Tomasello, G., Petrelli, F., Ghidini, M., Russo, A., Passalacqua, R., & Barni, S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0278 · Cited by 204
Mirkovic, J., McFarland, M., Garcia, E., Sholl, L. M., Lindeman, N., MacConaill, L., Dong, F., Hirsch, M., Nucci, M. R., Quick, C. M., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000958 · Cited by 166
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Caputo, F., Santini, C., Bardasi, C., Cerma, K., Casadei-Gardini, A., Spallanzani, A., Andrikou, K., Cascinu, S., & Gelsomino, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215369 · Cited by 162
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
Auclin, E., Zaanan, A., Vernerey, D., Douard, R., Gallois, C., Laurent-Puig, P., Bonnetain, F., & Taieb, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx030 · Cited by 159
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 168
Lyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.07.009 · Cited by 111
KRAS and BRAF Mutations in Stage II and III Colon Cancer: A Systematic Review and Meta-Analysis
Formica, V., Sera, F., Cremolini, C., Riondino, S., Morelli, C., Arkenau, H.-T., & Roselli, M. (2022) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab190 · Cited by 120
Recent developments in the treatment of metastatic colorectal cancer
Loree, J. M., & Kopetz, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714997 · Cited by 116
Van Cutsem, E., Taieb, J., Yaeger, R., Yoshino, T., Grothey, A., Maiello, E., Elez, E., Dekervel, J., Ross, P., Ruiz-Casado, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01693 · Cited by 103
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 95
BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape
Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02541 · Cited by 92
Unveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 102
Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., Zhuang, W., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.015 · Cited by 88
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations
Cercek, A., Braghiroli, M. I., Chou, J. F., Hechtman, J. F., Kemeny, N., Saltz, L., Capanu, M., & Yaeger, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0400 · Cited by 86
Advances in tests for colorectal cancer screening and diagnosis
Chan, S. C. H., & Liang, Q. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2065197 · Cited by 92
Goey, K. K. H., Elias, S. G., van Tinteren, H., Laclé, M. M., Willems, S. M., Offerhaus, G. J. A., de Leng, W. W. J., Strengman, E., ten Tije, A. J., Creemers, G. J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx322 · Cited by 88
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, W., Franchini, F., Alexander, M., Officer, A., Wong, H.-L., IJzerman, M., Desai, J., & Solomon, B. J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.030 · Cited by 75
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Taieb, J., Lapeyre-Prost, A., Laurent Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 74
Miao, Q., Deng, W.-Q., Lyu, W.-Y., Sun, Z.-T., Fan, S.-R., Qi, M., Qiu, S., Zhu, Y.-R., Lin, J.-P., Chen, M.-F., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.05.008 · Cited by 80
Stintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M., Kaiser, F., Kahl, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01420 · Cited by 69
Self-citationLoupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell’Aquila, E., Scartozzi, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.008 · Cited by 69
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Schirripa, M., Nappo, F., Cremolini, C., Salvatore, L., Rossini, D., Bensi, M., Businello, G., Pietrantonio, F., Randon, G., Fucà, G., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.009 · Cited by 66
Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis
Breuer, E., Hebeisen, M., Schneider, M. A., Roth, L., Pauli, C., Frischer-Ordu, K., Eden, J., Pache, B. C.-E., Steffen, T., Hübner, M., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab001 · Cited by 68
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Gómez‐España, M. A., Gallego-Plazas, J., González‐Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliú, J., & Vera, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02002-w · Cited by 72
Racial and Ethnic Disparities in Early-Onset Colorectal Cancer Survival
Zaki, T. A., Liang, P. S., May, F. P., & Murphy, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.035 · Cited by 70
Pan, M., Jiang, C., Tse, P., Achacoso, N., Alexeeff, S., Solorzano, A. V., Chung, E., Hu, W., Truong, T.-G., Arora, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02014 · Cited by 65
The application of radiomics in predicting gene mutations in cancer
Qi, Y., Zhao, T., & Han, M. (2022) · European Radiology · doi:10.1007/s00330-021-08520-6 · Cited by 60
Lawler, T., Parlato, L., & Andersen, S. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1349572 · Cited by 69
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 71
Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
Taïeb, J., Balogoun, R., Malicot, K. L., Tabernero, J. M., Mini, E., Folprecht, G., Laethem, J. V., Emile, J.-F., Mulot, C., Fratté, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw687 · Cited by 57
Strickler, J. H., Yoshino, T., Stevinson, K., Eichinger, C. S., Giannopoulou, C., Rehn, M., & Modest, D. P. (2023) · The Oncologist · doi:10.1093/oncolo/oyad138 · Cited by 54
Self-citationStudy of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
Ottaiano, A., Normanno, N., Facchini, S., Cassata, A., Nappi, A., Romano, C., Silvestro, L., De Stefano, A., Rachiglio, A. M., Roma, C., et al. (2020) · Cancers · doi:10.3390/cancers12071919 · Cited by 53
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65
Chida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K., Fushiki, K., Sawada, K., Kumanishi, R., Shirasu, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13870 · Cited by 50
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3053 · Cited by 49
Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac077 · Cited by 43
Loree, J. M., Wang, Y., Syed, M. A., Sorokin, A. V., Coker, O., Xiu, J., Weinberg, B. A., Vanderwalde, A. M., Tesfaye, A., Raymond, V. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0180 · Cited by 43
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Zhou, Y., Kuang, Y., Wang, C., Yu, Y., Pan, L., & Hu, X. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88779 · Cited by 56
Wang, J., Shen, J., Huang, C., Cao, M., & Shen, L. (2019) · Journal of Cancer · doi:10.7150/jca.30789 · Cited by 52
Mori, Y., Nyuya, A., Yasui, K., Toshima, T., Kawai, T., Taniguchi, F., Kimura, K., Inada, R., Nishizaki, M., Haraga, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24735 · Cited by 42
Cha, Y. J., Park, E. J., Baik, S. H., Lee, K. Y., & Kang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-48140-1 · Cited by 44
Yao, J., Zang, W., Ge, Y., Weygant, N., Yu, P., Li, L., Rao, G., Jiang, Z., Yan, R., He, L., et al. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/4248971 · Cited by 44
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Tria, S. M., Burge, M. E., & Whitehall, V. L. J. (2023) · Cancers · doi:10.3390/cancers15082375 · Cited by 38
Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and Therapeutic Implications
Shen, G., Liu, J., Wang, Y., Deng, Z., & Deng, F. (2025) · MedComm · doi:10.1002/mco2.70349 · Cited by 58
Fang, X., Zhu, N., Zhong, C., Wang, L., Li, J., Weng, S., Hu, H., Dong, C., Li, D., Song, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102123 · Cited by 38
Yousef, M., Yousef, A. M. G., Chowdhury, S., Fanaeian, M. M., Knafl, M., Peterson, J., Zeineddine, M. A. A., Alfaro, K. D., Zeineddine, F. A., Goldstein, D., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.3666 · Cited by 45
Goey, K. K. H., Sørbye, H., Glimelius, B. L. G., Adams, R., André, T., Arnold, D., Berlin, J. D., Bodoky, G., de Gramont, A., Díaz‐Rubio, E., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.010 · Cited by 35
Self-citationEdin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren‐Burström, A., Zingmark, C., Guelpen, B. R. V., Ljuslinder, I., Ling, A., & Palmqvist, R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02483-9 · Cited by 40
Ren, L., Zhu, D., Benson, A. B., Nordlinger, B., Koehne, C.-H., Delaney, C. P., Kerr, D. J., Lenz, H., Fan, J., Wang, J., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.02.019 · Cited by 37
Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
Lakatos, G., Köhne, C., & Bodoky, G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09913-7 · Cited by 33
Ahn, D. H., Ridinger, M., Cannon, T. L., Mendelsohn, L., Starr, J. S., Hubbard, J. M., Kasi, A., Barzi, A., Samuëlsz, E., Karki, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01266 · Cited by 43
Shapiro, G. I., LoRusso, P. M., Cho, D. C., Musib, L. C., Yan, Y., Wongchenko, M. J., Chang, I., Patel, P. H., Chan, I. T., Bohorquez, S. M. S., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00975-6 · Cited by 32
Sastre, J., de la Orden, V., Martínez, A., Bando, I., Balbı́n, M., Bellosillo, B., Palanca, S., Peligros, M. I., Mediero-Valeros, B., Llovet, P., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.014 · Cited by 31
Bouchahda, M., Saffroy, R., Karaboué, A., Hamelin, J., Innominato, P. F., Saliba, F., Lévi, F., Bosselut, N., & Lemoine, A. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00400 · Cited by 33
Agy, F. E., Bardai, S. E., Otmani, I. E., Benbrahim, Z., Karim, I. M. H., Mazaz, K., Benjelloun, E. B., Ousadden, A., Abkari, M. E., Ibrahimi, S. A., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248522 · Cited by 29
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer
Garajová, I., Ferracin, M., Porcellini, E., Palloni, A., Abbati, F., Biasco, G., & Brandi, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071547 · Cited by 28
Berger, M. D., Stintzing, S., Heinemann, V., Cao, S., Yang, D., Sunakawa, Y., Matsusaka, S., Ning, Y., Okazaki, S., Miyamoto, Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1663 · Cited by 32
Self-citationGazzaniga, P., Raimondi, C., Urbano, F., & Cortesi, E. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00277 · Cited by 28
Dai, D., Wang, Y., Zhu, L., Jin, H., & Wang, X. (2020) · PeerJ · doi:10.7717/peerj.9149 · Cited by 32
Cui, C., Duan, Y., Qiu, C., Wang, P., Sun, G., Ye, H., Dai, L., Han, Z., Song, C., Wang, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637871 · Cited by 26
Ohnmacht, A. J., Stahler, A., Stintzing, S., Modest, D. P., Holch, J. W., Westphalen, C. B., Hölzel, L., Schübel, M. K., Galhoz, A., Farnoud, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41011-4 · Cited by 33
Self-citationRoberto, M., Marchetti, P., Arrivi, G., Pietro, F. R. D., Cascinu, S., Gelsomino, F., Caputo, F., Cerma, K., Ghidini, M., Ratti, M., et al. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03589-9 · Cited by 42
Mei, Y., Qin, X., Yang, Z., Song, S., Liu, X., Wu, C., Qian, J., Huang, X., Zhang, Y., & He, W. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.10.003 · Cited by 36
Papachristos, A., Kemos, P., Κάτσιλα, Θ., Panoilia, E., Patrinos, G. P., Kalofonos, H. P., & Sivolapenko, G. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225791 · Cited by 26
Stahler, A., Stintzing, S., von Einem, J. C., Westphalen, C. B., Heinrich, K., Krämer, N., Michl, M., Modest, D. P., von Weikersthal, L. F., Decker, T. W., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.003 · Cited by 28
Self-citationGong, Q., Chen, X., Liu, F., & Cao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1216585 · Cited by 26
Froelich, M. F., Heinemann, V., Sommer, W. H., Holch, J. W., Schoeppe, F., Hesse, N., Baumann, A. B., Kunz, W. G., Reiser, M. F., Ricke, J., et al. (2018) · European Radiology · doi:10.1007/s00330-018-5454-7 · Cited by 26
Self-citationPerioperative Chemotherapy for Liver Metastasis of Colorectal Cancer
Chan, G. H. J., & Chee, C. E. (2020) · Cancers · doi:10.3390/cancers12123535 · Cited by 25
Takahashi, T., Yamazaki, K., Oki, E., Shiozawa, M., Mitsugi, K., Makiyama, A., Nakamura, M., Ojima, H., Kagawa, Y., Matsuhashi, N., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100093 · Cited by 23
Trunk, A. D., Braithwaite, M., Nevala-Plagemann, C., Pappas, L. M., Haaland, B. A., & Garrido‐Laguna, I. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7059 · Cited by 43
Osterlund, E., Ristimäki, A., Kytölä, S., Kuopio, T., Heervä, E., Muhonen, T., Halonen, P., Kallio, R., Soveri, L.-M., Sundström, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.826073 · Cited by 23
Bai, B., Shan, L., Xie, B., Huang, X., Mao, W., Wang, X., Wang, D., & Zhu, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7709 · Cited by 25
Modest, D. P., Heinemann, V., Folprecht, G., Denecke, T., Pratschke, J., Lang, H., Bemelmans, M. H. A., Becker, T., Rentsch, M., Seehofer, D., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08219-w · Cited by 26
Self-citationPrognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
Ucar, G., Ergun, Y., Aktürk Esen, S., Acikgoz, Y., Dirikoc, M., Esen, İ., Bal, Ö., & Uncu, D. (2020) · Medicine · doi:10.1097/md.0000000000022407 · Cited by 19
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
Wu, H., Binbin, J., Wei, Y., & Kun, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.561669 · Cited by 22
Sunakawa, Y., Satake, H., Usher, J. L., Jaimes, Y. S., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100512 · Cited by 24
Ottaiano, A., Sabbatino, F., Perri, F., Cascella, M., Sirica, R., Patrone, R., Capuozzo, M., Savarese, G., Ianniello, M., Petrillo, N., et al. (2023) · Cancers · doi:10.3390/cancers15143579 · Cited by 25
Ma, C., Huang, C., Chang, T., Tsai, H., Su, W., Yeh, Y., Chen, P.-J., & Wang, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.12.003 · Cited by 22
Stahler, A., Heinemann, V., Ricard, I., von Einem, J. C., Giessen-Jung, C., Westphalen, C. B., Michl, M., Heinrich, K., Miller-Phillips, L., Jelas, I., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03290-y · Cited by 21
Self-citationPaneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer
Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23
Fountzilas, C. K., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1650 · Cited by 27
Yang, Q., Huang, Y., Jiang, Z.-M., Wang, H., Li, W., Zhang, B., & Xie, D.-R. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s154220 · Cited by 21
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 18
Metadata
- Authors
- Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., Giessen-Jung, C., Stahler, A., Schmoll, H. J., Jung, A., Kirchner, T., Tannapfel, A., & Reinacher-Schick, A.
- Affiliations
- German Cancer Research Center (DE)
- Ludwig-Maximilians-Universität München (DE)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Kliniken Maria Hilf (DE)
- LMU Klinikum (DE)
- University Hospital in Halle (DE)
- Ruhr University Bochum (DE)
- Corresponding author
- Modest, D.P.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 27
- Issue
- 9
- Pages
- 1746-1753
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4999563
- OpenAlex
- W2465450966
- Semantic Scholar
- c6c03496c35c248a5905726558f97863fff59b9b
- Cited by
- 351
- References
- 31
- Citations by year
- 2026: 25 · 2025: 48 · 2024: 63 · 2023: 50 · 2022: 33 · 2021: 39 · 2020: 40 · 2019: 20 · 2018: 15 · 2017: 15 · 2016: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 1160 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, KRAS mutation, NRAS mutation, BRAF mutation, KRAS G12C, KRAS G13D, first-line therapy, progression-free survival, overall survival, predictive biomarkers, prognostic factors
- MeSH terms
- Female, Humans, Male, Membrane Proteins, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Randomized Controlled Trials as Topic, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease-Free Survival, GTP Phosphohydrolases, Proto-Oncogene Proteins B-raf, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.